Biodexa Hits 100-Patient Milestone in FAP Phase 3 Trial, Accelerates Timeline
Event summary
- Biodexa enrolled 100 patients in its Phase 3 Serenta trial for Familial Adenomatous Polyposis (FAP), ahead of schedule.
- The trial is recruiting across 29 US sites, 5 European countries, with 2 Canadian sites pending.
- Futility analysis could occur early 2027, with database lock by year-end 2027—sooner than initially projected.
- eRapa, the trial drug, has Orphan Drug Designation in the US and Europe.
- The Phase 3 program is supported by a $20M grant from the Cancer Prevention and Research Institute of Texas.
The big picture
Biodexa’s rapid enrollment in the Serenta trial reflects strong site participation and patient demand for FAP treatments, an area with no approved therapies. The accelerated timeline for futility analysis and database lock could position eRapa as a potential first-in-class treatment, though success hinges on maintaining recruitment momentum and positive clinical outcomes. The $20M CPRIT grant underscores the strategic importance of developing therapies for rare gastrointestinal cancers.
What we're watching
- Execution Risk
- Whether Biodexa can sustain the current enrollment pace to meet accelerated timelines for futility analysis and database lock.
- Regulatory Approval
- How the Phase 3 trial results will impact eRapa’s path to FDA and EMA approval, given its Orphan Drug Designation.
- Funding Dynamics
- The pace at which Biodexa utilizes its $20M CPRIT grant and whether additional capital will be needed to advance eRapa beyond Phase 3.
Related topics
